{"id":"deca","rwe":[{"pmid":"41897550","year":"2026","title":"Melatonin Ameliorates decaBDE-Induced Autism-Relevant Behaviors Through Promoting SIRT1/SIRT3/FOXO3a-Dependent Mitochondrial Quality Control.","finding":"","journal":"Antioxidants (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41859789","year":"2026","title":"[Non-respiratory lung function (problem status)].","finding":"","journal":"Terapevticheskii arkhiv","studyType":"Clinical Study"},{"pmid":"41833678","year":"2026","title":"Cooperative reading of DECA-CCAAT composite element by the TALE/NF-Y/Sp2 transcription factors.","finding":"","journal":"International journal of biological macromolecules","studyType":"Clinical Study"},{"pmid":"41831757","year":"2026","title":"Polybrominated diphenyl ethers (PBDEs) contaminations across environmental compartments in the Middle East and North Africa.","finding":"","journal":"Environmental research","studyType":"Clinical Study"},{"pmid":"41799318","year":"2026","title":"rac-4H,5H,6H,7H,8H,9H,10H,11H-Cyclo-deca-[d][1,2,3]selena-diazol-4-ol.","finding":"","journal":"IUCrData","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Baylor College of Medicine","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Parkinsonism","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Oculogyric crisis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Sedation","drugRate":"","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyskinesia","drugRate":"","severity":"common","organSystem":""},{"effect":"Dystonia","drugRate":"","severity":"common","organSystem":""},{"effect":"Cogwheel rigidity","drugRate":"","severity":"common","organSystem":""},{"effect":"Muscle rigidity","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertonia","drugRate":"","severity":"common","organSystem":""},{"effect":"Masked facies","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"","severity":"common","organSystem":""},{"effect":"Vision blurred","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperprolactinemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Weight increased","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site reaction","drugRate":"","severity":"common","organSystem":""},{"effect":"Salivary hypersecretion","drugRate":"","severity":"common","organSystem":""},{"effect":"Erectile dysfunction","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Neuroleptic malignant syndrome","drugRate":"","severity":"serious"},{"effect":"Tardive dyskinesia","drugRate":"","severity":"serious"},{"effect":"Sudden death","drugRate":"","severity":"serious"},{"effect":"Ventricular fibrillation","drugRate":"","severity":"serious"},{"effect":"Torsade de pointes","drugRate":"","severity":"serious"},{"effect":"Ventricular tachycardia","drugRate":"","severity":"serious"},{"effect":"Acute hepatic failure","drugRate":"","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"","severity":"serious"},{"effect":"Anaphylactic reaction","drugRate":"","severity":"serious"},{"effect":"Pancytopenia","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Dexamethasone (D)","Etoposide (E)","Cytarabine (A)","Cisplatin (C)"],"company":"Baylor College of Medicine","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DECA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:28:15.697927+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:28:22.521906+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DECA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:28:23.511926+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL12482/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:28:24.187121+00:00"}},"allNames":["deca"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Deca's mechanism of action is not well understood, but it is believed to involve the modulation of a specific molecular target, potentially through competitive inhibition or allosteric regulation."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=deca","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=deca","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:38:32.198965","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:28:26.117931+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"deca","indications":{"approved":[{"name":"Antiseptic preparation","diseaseId":"antiseptic-preparation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":525,"completionDate":"2026-09-18"},{"nctId":"NCT04747912","phase":"PHASE2","title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","status":"SUSPENDED","sponsor":"University of Chicago","startDate":"2021-03-02","conditions":["Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia","ph+ Acute Lymphoblastic Leukemia"],"enrollment":25,"completionDate":"2027-03-01"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":["Recurrent AL Amyloidosis","Refractory AL Amyloidosis"],"enrollment":24,"completionDate":"2026-06-30"},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT07494136","phase":"PHASE4","title":"Dose Dependent Steroid Injections","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05","conditions":["Lumbar Radiculopathy","Sciatica","Back Pain With Radiation"],"enrollment":150,"completionDate":"2027-05"},{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":["Multiple Myeloma"],"enrollment":28,"completionDate":"2027-06-01"},{"nctId":"NCT06235567","phase":"PHASE1,PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT05519085","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Celgene","startDate":"2022-09-20","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":810,"completionDate":"2033-11-30"},{"nctId":"NCT01297764","phase":"PHASE1,PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":["Multiple Myeloma"],"enrollment":17,"completionDate":"2026-07"},{"nctId":"NCT02773030","phase":"PHASE1,PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":["Multiple Myeloma"],"enrollment":466,"completionDate":"2028-07-28"},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":["Prostatic Neoplasms","Metastatic Castration-Resistant Prostate Cancer"],"enrollment":14,"completionDate":"2026-03-09"},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":["Marginal Zone Lymphoma(MZL)"],"enrollment":65,"completionDate":"2029-10-02"},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":["Clonal Cytopenia of Undetermined Significance","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia"],"enrollment":80,"completionDate":"2033-11-02"},{"nctId":"NCT02491632","phase":"PHASE2,PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":["Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT06207123","phase":"PHASE1,PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":["Acute Leukemia","Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":15,"completionDate":"2026-12-01"},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":["Multiple Myeloma"],"enrollment":75,"completionDate":"2031-03"},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma"],"enrollment":53,"completionDate":"2029-03-30"},{"nctId":"NCT05552976","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-10","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":525,"completionDate":"2029-07-25"},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":["Multiple Myeloma"],"enrollment":30,"completionDate":"2026-07"},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":30,"completionDate":"2031-12-31"},{"nctId":"NCT06348108","phase":"PHASE1","title":"Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alfred Chung, MD","startDate":"2025-07-28","conditions":["Multiple Myeloma","Refractory Multiple Myeloma","Relapsed Multiple Myeloma"],"enrollment":32,"completionDate":"2029-07-31"},{"nctId":"NCT03661645","phase":"PHASE4","title":"Post-operative Methylprednisolone Taper Course for Orthopedic Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Emory University","startDate":"2018-09-07","conditions":["Orthopedic Surgeries"],"enrollment":500,"completionDate":"2029-01"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":["Multiple Myeloma"],"enrollment":33,"completionDate":"2026-05-07"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT01572480","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":["Multiple Myeloma"],"enrollment":55,"completionDate":"2025-02-28"},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":["Malignant Neoplasm"],"enrollment":250,"completionDate":"2027-11-04"},{"nctId":"NCT05730036","phase":"PHASE3","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-09-18","conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"enrollment":410,"completionDate":"2033-04-19"},{"nctId":"NCT06104449","phase":"PHASE1","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-14","conditions":["Prostatic Neoplasms","Metastatic Castration-Resistant Prostate Cancer"],"enrollment":6,"completionDate":"2026-04-20"},{"nctId":"NCT04094961","phase":"PHASE1,PHASE2","title":"Ixazomib + Pomalidomide + Dexamethasone In MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2019-09-18","conditions":["Multiple Myeloma","Multiple Myeloma in Relapse"],"enrollment":52,"completionDate":"2027-01-01"},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":3,"completionDate":"2026-08-31"},{"nctId":"NCT05023369","phase":"PHASE4","title":"This is a Study to Verify if Periarticular Hip Injection of Corticosteroid After Hip Replacement Reduce the Pain and the Hospitalisation Time","status":"RECRUITING","sponsor":"Ente Ospedaliero Cantonale, Bellinzona","startDate":"2021-12-10","conditions":["Femoral Neck Fractures"],"enrollment":110,"completionDate":"2026-11-01"},{"nctId":"NCT06930690","phase":"PHASE1,PHASE2","title":"Dexamethasone for Ureteral STent Symptoms (DUSTS)","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":["Ureteral Stent-Related Symptom"],"enrollment":70,"completionDate":"2027-04"},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Mixed Phenotype Acute Leukemia"],"enrollment":850,"completionDate":"2039-05"},{"nctId":"NCT05257941","phase":"PHASE1,PHASE2","title":"ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery","status":"TERMINATED","sponsor":"Indiana University","startDate":"2022-01-27","conditions":["Surgery"],"enrollment":116,"completionDate":"2024-08-29"},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":["Plasma Cell Myeloma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma"],"enrollment":1450,"completionDate":"2027-12-31"},{"nctId":"NCT04977427","phase":"PHASE4","title":"Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2021-08-31","conditions":["Cataract Diabetic","Macula Edema"],"enrollment":0,"completionDate":"2021-12-20"},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":288,"completionDate":"2029-12-31"},{"nctId":"NCT03283917","phase":"PHASE1","title":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-07","conditions":["Newly Diagnosed Primary Amyloidosis","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis"],"enrollment":21,"completionDate":"2027-05-18"},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":["T-cell Acute Lymphoblastic Leukemia","T-cell Lymphoma","Mixed Phenotype Acute Leukemia"],"enrollment":100,"completionDate":"2033-12"},{"nctId":"NCT06664853","phase":"PHASE3","title":"Open-Label Extension of EryDex Study IEDAT-04-2022","status":"TERMINATED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-12-11","conditions":["Ataxia Telangiectasia"],"enrollment":101,"completionDate":"2026-01-30"},{"nctId":"NCT04764942","phase":"PHASE1,PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":39,"completionDate":"2027-12-17"},{"nctId":"NCT07428369","phase":"PHASE2,PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":["Multiple Myeloma (MM)"],"enrollment":1570,"completionDate":"2038-05-21"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT05972135","phase":"PHASE2","title":"Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-10-23","conditions":["Multiple Myeloma"],"enrollment":100,"completionDate":"2027-10"},{"nctId":"NCT05530421","phase":"PHASE2","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-03-26","conditions":["Relapsed and Refractory Multiple Myeloma"],"enrollment":33,"completionDate":"2030-03-26"},{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":["Corneal Edema","Corneal Defect","Anterior Chamber Inflammation","Ocular Pain","Corneal Staining","Visual Outcome","CME - Cystoid Macular Edema"],"enrollment":50,"completionDate":"2025-02-05"},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":21,"completionDate":"2028-02-01"},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":["AL Amyloidosis"],"enrollment":11,"completionDate":"2026-07-24"},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":["Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA"],"enrollment":158,"completionDate":"2029-06-30"},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":["Multiple Myeloma"],"enrollment":18,"completionDate":"2026-09"},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Burkitt Leukemia","Recurrent Burkitt Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Acute Lymphoblastic Leukemia","Refractory Burkitt Leukemia","Refractory Burkitt Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Lymphoblastic Lymphoma"],"enrollment":42,"completionDate":"2027-08-01"},{"nctId":"NCT04432597","phase":"PHASE1,PHASE2","title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-11","conditions":["HPV Positive Cancer","Vulvar, Vaginal, Penile, Rectal Cancer","Anal Cancer","Oropharyngeal Cancer","Cervical Cancer"],"enrollment":39,"completionDate":"2026-03-31"},{"nctId":"NCT05978622","phase":"","title":"Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-10-30","conditions":["Diabetic Macular Edema"],"enrollment":236,"completionDate":"2026-06"},{"nctId":"NCT07099222","phase":"PHASE1,PHASE2","title":"Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arizona","startDate":"2024-10-10","conditions":["Postoperative Pain","Nausea and Vomiting, Postoperative","Dizziness","Constipation","Duration of Response","Narcotics Consumption","Pain After Surgery"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":128,"completionDate":"2034-05"},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":["Mantle Cell Lymphoma"],"enrollment":51,"completionDate":"2027-03-22"},{"nctId":"NCT07208799","phase":"PHASE2","title":"Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures","status":"RECRUITING","sponsor":"Nishtar Medical University","startDate":"2026-01-03","conditions":["Mandible Fracture","Edema Face","Pain Management","Corticosteroid Injection"],"enrollment":72,"completionDate":"2026-12-01"},{"nctId":"NCT04371445","phase":"PHASE4","title":"Dextenza in the Post-op Management of Vitreoretinal Surgeries","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-06-01","conditions":["Vitreoretinal Surgery","Ocular Inflammation","Post-operative Pain","Post-Operative Inflammation"],"enrollment":30,"completionDate":"2026-05-01"},{"nctId":"NCT04661137","phase":"PHASE2","title":"A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma","status":"SUSPENDED","sponsor":"Hackensack Meridian Health","startDate":"2021-03-16","conditions":["Multiple Myeloma"],"enrollment":96,"completionDate":"2027-02"},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":["Multiple Myeloma"],"enrollment":94,"completionDate":"2027-12-31"},{"nctId":"NCT05488847","phase":"PHASE4","title":"Opioid-Free Pain Protocol After Shoulder Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2022-06-25","conditions":["Shoulder Arthropathy","Shoulder Pain"],"enrollment":83,"completionDate":"2026-09-01"},{"nctId":"NCT06132685","phase":"PHASE2","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-09","conditions":["Low Grade Glioma","Malignant Brain Glioma","Malignant Brain Neoplasm","Meningioma"],"enrollment":200,"completionDate":"2028-07-30"},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":["Plasmacytoma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":35,"completionDate":"2024-07-24"},{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":["Atopic Keratoconjunctivitis"],"enrollment":138,"completionDate":"2027-05"},{"nctId":"NCT04303065","phase":"PHASE3","title":"Trial of Dexamethasone for Traumatic Brain Injured Patients With Brain Contusions and Pericontusional Edema","status":"TERMINATED","sponsor":"Jon Pérez Bárcena","startDate":"2020-07-24","conditions":["Traumatic Brain Injury","Cerebral Edema","Head Injury Trauma"],"enrollment":600,"completionDate":"2025-12-01"},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":["B-Cell Non-Hodgkin Lymphoma (B-NHL)"],"enrollment":216,"completionDate":"2027-05-14"},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":["Multiple Myeloma"],"enrollment":177,"completionDate":"2027-08"},{"nctId":"NCT07388069","phase":"PHASE1,PHASE2","title":"Study of TN-001 Topical Eyedrops for Keratoconus","status":"ENROLLING_BY_INVITATION","sponsor":"TheiaNova Ltd.","startDate":"2025-12-23","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2027-07-01"},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":["ISS Stage III Plasma Cell Myeloma","Multiple Myeloma"],"enrollment":17,"completionDate":"2028-11-20"},{"nctId":"NCT05981209","phase":"PHASE1","title":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","status":"RECRUITING","sponsor":"Abdullah Khan","startDate":"2023-12-21","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":27,"completionDate":"2026-12-31"},{"nctId":"NCT06988488","phase":"PHASE1,PHASE2","title":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-10-07","conditions":["Multiple Myeloma"],"enrollment":62,"completionDate":"2027-06-03"},{"nctId":"NCT04414475","phase":"PHASE2","title":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-07-01","conditions":["Multiple Myeloma, Refractory"],"enrollment":127,"completionDate":"2028-01"},{"nctId":"NCT07378215","phase":"PHASE4","title":"The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study","status":"NOT_YET_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2026-02","conditions":["Postoperative Quality of Recovery","Health-Related Quality-of-Life","Quality of Life"],"enrollment":224,"completionDate":"2027-02"},{"nctId":"NCT05016947","phase":"PHASE1","title":"Venetoclax Plus Inotuzumab for B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-09-24","conditions":["B-cell Acute Lymphoblastic Leukemia","B-Cell Lymphoma","ALL"],"enrollment":23,"completionDate":"2026-12-23"},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":["Multiple Myeloma"],"enrollment":50,"completionDate":"2026-03-30"},{"nctId":"NCT06213649","phase":"PHASE3","title":"Parasitic Ulcer Treatment Trial","status":"RECRUITING","sponsor":"Jeremy Keenan, MD, MPH","startDate":"2024-07-01","conditions":["Acanthamoeba Keratitis"],"enrollment":232,"completionDate":"2028-07"},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":["Recurrent Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hairy Cell Leukemia","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent T Acute Lymphoblastic Leukemia","Refractory Acute Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Hairy Cell Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory T Acute Lymphoblastic Leukemia","Systemic Mastocytosis"],"enrollment":13,"completionDate":"2025-08-05"},{"nctId":"NCT07216820","phase":"NA","title":"Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-01-21","conditions":["Shoulder Surgery","Obesity"],"enrollment":68,"completionDate":"2027-11-15"},{"nctId":"NCT04240054","phase":"PHASE2","title":"Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-02","conditions":["Multiple Myeloma"],"enrollment":41,"completionDate":"2030-12-01"},{"nctId":"NCT05720949","phase":"PHASE4","title":"Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2023-01-12","conditions":["ACL","Anterior Cruciate Ligament Injuries"],"enrollment":192,"completionDate":"2024-12-02"},{"nctId":"NCT06616584","phase":"PHASE2,PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":378,"completionDate":"2028-12-31"},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":["Multiple Myeloma"],"enrollment":729,"completionDate":"2026-12"},{"nctId":"NCT02718833","phase":"PHASE2","title":"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2016-06-21","conditions":["Multiple Myeloma"],"enrollment":52,"completionDate":"2027-12"},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":["Acute Lymphoblastic Leukemia, Pediatric"],"enrollment":560,"completionDate":"2034-11"},{"nctId":"NCT07345819","phase":"NA","title":"Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis","status":"NOT_YET_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2026-04-01","conditions":["Orbital Cellulitis"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT07343128","phase":"PHASE2,PHASE3","title":"Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia","status":"COMPLETED","sponsor":"Sanliurfa Education and Research Hospital","startDate":"2025-06-01","conditions":["Fibromyalgia"],"enrollment":68,"completionDate":"2025-12-25"},{"nctId":"NCT02813135","phase":"PHASE1,PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":["Pediatric Cancer"],"enrollment":472,"completionDate":"2031-02"},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":["Multiple Myeloma","Triple Negative Breast Cancer","Duffy Blood Group, Chemokine Receptor Gene Mutation","Duffy Blood Group, Chemokine Receptor Gene C.-67T>C"],"enrollment":90,"completionDate":"2029-03-31"},{"nctId":"NCT01562405","phase":"PHASE1","title":"Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":["Multiple Myeloma"],"enrollment":33,"completionDate":"2027-12"},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":["Multiple Myeloma"],"enrollment":46,"completionDate":"2025-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL12482"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Baylor College of Medicine","relationship":"Original Developer"}],"publicationCount":1882,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Baylor College of Medicine","recentPublications":[{"date":"2026 Mar 23","pmid":"41897550","title":"Melatonin Ameliorates decaBDE-Induced Autism-Relevant Behaviors Through Promoting SIRT1/SIRT3/FOXO3a-Dependent Mitochondrial Quality Control.","journal":"Antioxidants (Basel, Switzerland)"},{"date":"2026 Mar 17","pmid":"41859789","title":"[Non-respiratory lung function (problem status)].","journal":"Terapevticheskii arkhiv"},{"date":"2026 Mar 13","pmid":"41833678","title":"Cooperative reading of DECA-CCAAT composite element by the TALE/NF-Y/Sp2 transcription factors.","journal":"International journal of biological macromolecules"},{"date":"2026 Mar 12","pmid":"41831757","title":"Polybrominated diphenyl ethers (PBDEs) contaminations across environmental compartments in the Middle East and North Africa.","journal":"Environmental research"},{"date":"2026 Feb","pmid":"41799318","title":"rac-4H,5H,6H,7H,8H,9H,10H,11H-Cyclo-deca-[d][1,2,3]selena-diazol-4-ol.","journal":"IUCrData"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","brandName":"DECA","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:28:26.117931+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}